NATCO’s Erdafitinib is indicated for the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma harbouring susceptible FGFR3 genetic alteration
The biosimilar Ustekinumab has been developed and manufactured by the company
Biocon Biologics earlier announced a settlement agreement in the United States for a Bmab 1200 launch no later than February 22, 2025
The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA
Lupin enters into BTA with Lupin Manufacturing Solutions
Erdafitinib is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma
According to IQVIA sales data for the 12-month period ending March 2022, the Zytiga tablets, 500 mg market achieved annual sales of approximately US $ 260.2 million
Subscribe To Our Newsletter & Stay Updated
